Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States
Nivolumab plus gemcitabine-cisplatin first-line treatment for advanced urothelial carcinoma results in longer life expectancy than gemcitabine-cisplatin, but is not cost-effective in China at current price. However, cost-effectiveness is likely to be achieved in most patient subgroups in the US.
Authors
- Guiyuan Xiang
- Yunqi Ding (ORCID: https://orcid.org/0000-0002-1677-7696)
- Linning Wang
- Lanlan Gan
- Yue-Yue Huang
- Yuanlin Wu
- Haiyan Xing (ORCID: https://orcid.org/0000-0001-9864-9550)
- Yao Liu (ORCID: https://orcid.org/0009-0000-1843-0517)
Institutions
- Army Medical University (CN)
- China Pharmaceutical University (CN)
- Daping Hospital (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.3389/fimmu.2024.1426024
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15